FOLFOX-HAIC对比TACE一线治疗不可切除大肝癌的III期随机试验
这项多中心随机III期试验纳入315例不可切除、最大径≥7 cm且无大血管侵犯或肝外转移的肝细胞癌患者,比较FOLFOX-HAIC与TACE一线治疗。
要点
- FOLFOX-HAIC较TACE显著延长不可切除大肝癌患者的中位总生存期(23.1 vs 16.1个月)。
- FOLFOX-HAIC组缓解率46%、中位无进展生存期9.6个月,均优于TACE组。
- TACE组严重不良事件发生率30%,高于FOLFOX-HAIC组的19%。
核心结论
- 在不可切除大肝癌患者中,FOLFOX-HAIC一线治疗的总生存期显著优于TACE。
研究设计与样本
- 随机、多中心、开放标签III期试验,纳入315例不可切除肝细胞癌(最大径≥7 cm、无大血管侵犯或肝外转移)成人患者,1:1随机分配至FOLFOX-HAIC组(n=159)或TACE组(n=156)。
- 主要终点为意向性治疗分析的总生存期,安全性在至少接受1个周期治疗的患者中评估。
主要发现
- FOLFOX-HAIC组和TACE组各有2例死亡被认为与治疗相关。
关键数值与推荐
- FOLFOX-HAIC方案:奥沙利铂130 mg/m²、亚叶酸钙400 mg/m²、氟尿嘧啶推注400 mg/m²(第1天)、氟尿嘧啶输注2400 mg/m²持续24小时,每3周一次。
- TACE方案:表柔比星50 mg、洛铂50 mg、碘油及聚乙烯醇颗粒。
临床怎么用
- 对于不可切除、最大径≥7 cm且无大血管侵犯或肝外转移的肝细胞癌,可考虑FOLFOX-HAIC作为优于TACE的一线治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In a previous phase II trial, hepatic arterial infusion chemotherapy (HAIC) with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment responses than transarterial chemoembolization (TACE) in large unresectable hepatocellular carcinoma. We aimed to compare the overall survival of patients treated with FOLFOX-HAIC versus TACE as first-line treatment in this population. METHODS: In this randomized, multicenter, open-label trial, adults with unresectable hepatocellular carcinoma (largest diameter ≥ 7 cm) without macrovascular invasion or extrahepatic spread were randomly assigned 1:1 to FOLFOX-HAIC (oxaliplatin 130 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2,400 mg/m2 for 24 hours, once every 3 weeks) or TACE (epirubicin 50 mg, lobaplatin 50 mg, and lipiodol and polyvinyl alcohol particles). The primary end point was overall survival by intention-to-treat analysis. Safety was assessed in patients who received ≥ 1 cycle of study treatment. RESULTS: Between October 1, 2016, and November 23, 2018, 315 patients were randomly assigned to FOLFOX-HAIC (n = 159) or TACE (n = 156). The median overall survival in the FOLFOX-HAIC group was 23.1 months (95% CI, 18.5 to 27.7) versus 16.1 months (95% CI, 14.3 to 17.9) in the TACE group (hazard ratio, 0.58; 95% CI, 0.45 to 0.75; P < .001). The FOLFOX-HAIC group showed a higher response rate than the TACE group (73 [46%] v 28 [18%]; P < .001) and a longer median progression-free survival (9.6 [95% CI, 7.4 to 11.9] v 5.4 months [95% CI, 3.8 to 7.0], P < .001). The incidence of serious adverse events was higher in the TACE group than in the FOLFOX-HAIC group (30% v 19%, P = .03). Two deaths in the FOLFOX-HAIC group and two in the TACE group were deemed to be treatment-related. CONCLUSION: FOLFOX-HAIC significantly improved overall survival over TACE in patients with unresectable large hepatocellular carcinoma.
引用
- Li QJ, He MK, Chen HW, et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol. 2021. PMID: 34648352. doi:10.1200/JCO.21.00608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。